Cargando…

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer

Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness,...

Descripción completa

Detalles Bibliográficos
Autores principales: Piras, Marta, Panebianco, Martina, Garibaldi, Matteo, Roberto, Michela, Merlonghi, Gioia, Pellegrini, Patrizia, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161769/
https://www.ncbi.nlm.nih.gov/pubmed/34073827
http://dx.doi.org/10.3390/curroncol28030182
_version_ 1783700571713175552
author Piras, Marta
Panebianco, Martina
Garibaldi, Matteo
Roberto, Michela
Merlonghi, Gioia
Pellegrini, Patrizia
Marchetti, Paolo
author_facet Piras, Marta
Panebianco, Martina
Garibaldi, Matteo
Roberto, Michela
Merlonghi, Gioia
Pellegrini, Patrizia
Marchetti, Paolo
author_sort Piras, Marta
collection PubMed
description Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer. Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable.
format Online
Article
Text
id pubmed-8161769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81617692021-05-29 A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer Piras, Marta Panebianco, Martina Garibaldi, Matteo Roberto, Michela Merlonghi, Gioia Pellegrini, Patrizia Marchetti, Paolo Curr Oncol Case Report Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer. Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable. MDPI 2021-05-24 /pmc/articles/PMC8161769/ /pubmed/34073827 http://dx.doi.org/10.3390/curroncol28030182 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Piras, Marta
Panebianco, Martina
Garibaldi, Matteo
Roberto, Michela
Merlonghi, Gioia
Pellegrini, Patrizia
Marchetti, Paolo
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title_full A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title_fullStr A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title_full_unstemmed A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title_short A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
title_sort case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in her2-positive early breast cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161769/
https://www.ncbi.nlm.nih.gov/pubmed/34073827
http://dx.doi.org/10.3390/curroncol28030182
work_keys_str_mv AT pirasmarta acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT panebiancomartina acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT garibaldimatteo acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT robertomichela acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT merlonghigioia acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT pellegrinipatrizia acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT marchettipaolo acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT pirasmarta caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT panebiancomartina caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT garibaldimatteo caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT robertomichela caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT merlonghigioia caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT pellegrinipatrizia caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer
AT marchettipaolo caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer